HCC1500 (ATCC® CRL-2329)

Organism: Homo sapiens, human  /  Cell Type: Epithelial  /  Tissue: mammary gland; breast/duct  /  Disease: TNM stage IIB, grade 2, primary ductal carcinoma

Permits and Restrictions

View Restrictions

Organism Homo sapiens, human
Tissue
mammary gland; breast/duct
Cell Type Epithelial
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease TNM stage IIB, grade 2, primary ductal carcinoma
Age 32 years
Gender female
Ethnicity Black
Storage Conditions liquid nitrogen vapor phase
Karyotype near diploid
Derivation
This cell line was initiated on 2/8/95 from a patient with a significant family history of early-onset colon cancer as well as a sister with breast cancer. The cell line took 14 months to establish.
Clinical Data
32 years
Black
female
Receptor Expression
estrogen receptor
progesterone receptor
Oncogene her2/neu -, p53 +
Genes Expressed
Epithelial glycoprotein 2 (EGP2),cytokeratin 19,her2/neu -, p53 +,The cells are negative for expression of Her2-neu but positive for expression of p53. The cells are positive for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene.
Cellular Products
Epithelial glycoprotein 2 (EGP2)
cytokeratin 19
Comments
The tumor was classified as TNM stage IIB, grade 2, invasive ductal carcinoma with 4 out of 24 lymph node metastasis.
The cells are poorly differentiated.
The cells are negative for expression of Her2-neu but positive for expression of p53.
HCC1500 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are positive for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).
HCC1500 contains a homozygous deletion at 3p21.3.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing

Protocol:

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Every 3 to 5 days
Cryopreservation
Freeze Medium: Complete growth medium 95%; DMSO, 5%
Storage Temperature: Liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 10
D13S317: 10
D16S539: 9,10
D5S818: 11,13
D7S820: 11
THO1: 9
TPOX: 8
vWA: 13,16
Name of Depositor AF Gazdar, AK Virmani
Year of Origin February 8, 1995
References

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Sekido Y, et al. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 16: 3151-3157, 1998. PubMed: 9671394

Basic Documentation
Restrictions

The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.

References

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Sekido Y, et al. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 16: 3151-3157, 1998. PubMed: 9671394